RSS-Feed abonnieren

DOI: 10.1055/s-0045-1811943
Circular RNA hsa_circ_0001666 and Its Target Protein ETV4 AS Potential Biomarkers for Crohn's Disease
Autoren
Funding The authors declare that they have not received funding from agencies in the public, private, or nonprofit sectors to conduct the present study.
Abstract
Introduction
Circular RNAs are stable non-coding RNAs that regulate key biological processes. Hsa_circ_0001666 was shown to be involved in several cancers and in chronic inflammatory diseases. It is overexpressed in Crohn's Disease (CD) and is associated with cell migration, invasion, epithelial-mesenchymal transition (EMT), and fibrosis. Hsa_circ_0001666 acts as a sponge for multiple microRNAs (miRNAs). Some of these miRNAs regulate the expression of ETS variant transcription factor 4 (ETV4), a protein regulating critical genes implicated in inflammation, invasion, and EMT.
Objectives
To assess the plasma relative expression levels of hsa_circ_0001666 and the ETV4 protein levels to evaluate their contribution to CD development and the possibility of utilizing them as potential non-invasive biomarkers for diagnosis of CD and assessment of the disease activity.
Material and Methods
The present study included 25 patients with active CD, 25 patients with inactive CD, and 25 healthy subjects as controls. The analysis of the relative expression of hsa_circ_0001666 in plasma was performed using the real-time quantitative polymerase chain reaction (qPCR) method. The ETV4 concentration in plasma was measured using an enzyme-linked immunosorbent assay (ELISA).
Results
Plasma expression levels of hsa_circ_0001666 and ETV4 protein were significantly higher in active and inactive CD patients than the healthy controls, and in active CD patients than in patients with inactive disease. Furthermore, there was a significant positive correlation between hsa_circ_0001666 to ETV4 expression in the three studied groups.
Conclusion
Higher levels of hsa_circ_0001666 and ETV4 in CD patients suggest their role in disease development and activity, and their potential use as diagnostic biomarkers and therapeutic targets for CD management.
Authors' Contribution
WNR: writing and editing; FDA: writing and editing; AFK: review and approval of the final version; NAB: review and approval of the final version; AMI: review and approval of the final version. All authors contributed equally to data collection, implementation of the experiment, analysis, and interpretation of results.
Publikationsverlauf
Eingereicht: 13. Mai 2025
Angenommen: 04. August 2025
Artikel online veröffentlicht:
25. September 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil
Walaa N. Roushdy, Amel F. Ketat, Nadia A. Barghash, Abeer M. Ibrahim, Fatma D. Alfarjani. Circular RNA hsa_circ_0001666 and Its Target Protein ETV4 AS Potential Biomarkers for Crohn's Disease. Journal of Coloproctology 2025; 45: s00451811943.
DOI: 10.1055/s-0045-1811943
-
References
- 1 Lightner AL, McKenna NP, Alsughayer A. et al. Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients. J Pediatr Surg 2019; 54 (10) 2162-2165
- 2 Cockburn E, Kamal S, Chan A. et al. Crohn's disease: an update. Clin Med (Lond) 2023; 23 (06) 549-557
- 3 Chen P, Zhou G, Lin J. et al. Serum Biomarkers for Inflammatory Bowel Disease. Front Med (Lausanne) 2020; 7: 123
- 4 Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol 2014; 32 (05) 453-461
- 5 Qiao YQ, Cai CW, Shen J, Zheng Q, Ran ZH. Circular RNA expression alterations in colon tissues of Crohn's disease patients. Mol Med Rep 2019; 19 (05) 4500-4506
- 6 Hu YA, Zhu Y, Liu G. et al. Expression profiles of circular RNAs in colon biopsies from Crohn's disease patients by microarray analysis. J Clin Lab Anal 2021; 35 (06) e23788
- 7 Iguchi A, Kitajima I, Yamakuchi M. et al. PEA3 and AP-1 are required for constitutive IL-8 gene expression in hepatoma cells. Biochem Biophys Res Commun 2000; 279 (01) 166-171
- 8 Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002; 277 (21) 18649-18657
- 9 Kapila S, Xie Y, Wang W. Induction of MMP-1 (collagenase-1) by relaxin in fibrocartilaginous cells requires both the AP-1 and PEA-3 promoter sites. Orthod Craniofac Res 2009; 12 (03) 178-186
- 10 Pellecchia A, Pescucci C, De Lorenzo E. et al. Overexpression of ETV4 is oncogenic in prostate cells through promotion of both cell proliferation and epithelial to mesenchymal transition. Oncogenesis 2012; 1 (07) e20
- 11 Qi Y, He J, Zhang Y. et al. Circular RNA hsa_circ_0001666 sponges miR–330–5p, miR–193a–5p and miR–326, and promotes papillary thyroid carcinoma progression via upregulation of ETV4. Oncol Rep 2021; 45 (04) 50
- 12 Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 1 (8167) 514
- 13 Brodersen JB, Kjeldsen J, Knudsen T, Jensen MD. Endoscopic severity and classification of lesions with pan-enteric capsule endoscopy and ileocolonoscopy in ileocolonic Crohn's disease. Endosc Int Open 2023; 11 (01) E32-E38
- 14 Sriram H, Khanka T, Kedia S. et al. Improved protocol for plasma microRNA extraction and comparison of commercial kits. Biochem Med (Zagreb) 2021; 31 (03) 030705
- 15 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25 (04) 402-408
- 16 Šimundić AM. Measures of diagnostic accuracy: Basic definitions. EJIFCC 2009; 19 (04) 203-211
- 17 Dolinger M, Torres J, Vermeire S. Crohn's disease. Lancet 2024; 403 (10432): 1177-1191
- 18 Long D, Wang C, Huang Y, Mao C, Xu Y, Zhu Y. Changing epidemiology of inflammatory bowel disease in children and adolescents. Int J Colorectal Dis 2024; 39 (01) 73
- 19 Lichtenstein GR, Shahabi A, Seabury SA. et al. Increased Lifetime Risk of Intestinal Complications and Extraintestinal Manifestations in Crohn's Disease and Ulcerative Colitis. Gastroenterol Hepatol (N Y) 2022; 18 (01) 32-43
- 20 Li L, Cheng R, Wu Y, Lin H, Gan H, Zhang H. Diagnosis and management of inflammatory bowel disease. J Evid Based Med 2024; 17 (02) 409-433
- 21 Conn VM, Chinnaiyan AM, Conn SJ. Circular RNA in cancer. Nat Rev Cancer 2024; 24 (09) 597-613
- 22 Li J, Xu JZ, Dou B. et al. Circ_0001666 upregulation promotes intestinal epithelial cell fibrosis in pediatric Crohn's disease via the SRSF1/BMP7 axis. Kaohsiung J Med Sci 2023; 39 (10) 966-977
- 23 Zhang R, Zhu W, Ma C, Ai K. Silencing of circRNA circ_0001666 Represses EMT in Pancreatic Cancer Through Upregulating miR-1251 and Downregulating SOX4. Front Mol Biosci 2021; 8: 684866
- 24 Wang X, Li R, Feng L. et al. Hsa_circ_0001666 promotes non-small cell lung cancer migration and invasion through miR-1184/miR-548I/AGO1 axis. Mol Ther Oncolytics 2022; 24: 597-611
- 25 Su N, Liu L, He S, Zeng L. Circ_0001666 affects miR-620/WNK2 axis to inhibit breast cancer progression. Genes Genomics 2021; 43 (08) 947-959
- 26 Bai F, Zuo C, Ouyang Y, Xiao K, He Z, Yang Z. Circular RNA 0001666 inhibits colorectal cancer cell proliferation, invasion and stemness by inactivating the Wnt/β-catenin signaling pathway and targeting microRNA-1229. Oncol Lett 2022; 23 (05) 153
- 27 Zhou J, Wang L, Sun Q. et al. Hsa_circ_0001666 suppresses the progression of colorectal cancer through the miR-576-5p/PCDH10 axis. Clin Transl Med 2021; 11 (11) e565
- 28 Fonseca AS, Ramão A, Bürger MC. et al. ETV4 plays a role on the primary events during the adenoma-adenocarcinoma progression in colorectal cancer. BMC Cancer 2021; 21 (01) 207
- 29 Shi Y, Ma C, Wu S. et al. ETS translocation variant 5 (ETV5) promotes CD4+ T cell-mediated intestinal inflammation and fibrosis in inflammatory bowel diseases. Mucosal Immunol 2024; 17 (04) 584-598
